It has been nearly 18 months since SHM launched the VTE Prevention Collaborative, which offers individualized assistance to hospitalists wishing to take the lead on reducing the incidence of preventable, hospital-acquired VTE at their sites.
The collaborative features two technical assistance options: a full year of distance mentoring or a one-day evaluation and consultation visit to the enrollee’s hospital. The project is led by Gregory Maynard, MD, and Jason Stein, MD. Both are stellar clinicians with quality improvement (QI) expertise and experience leading VTE prevention efforts. Dr. Maynard is head of the Division of Hospital Medicine and associate clinical professor of medicine at the University of California-San Diego. Dr. Stein is a hospitalist at Atlanta’s Emory University Hospital, assistant professor of Medicine at Emory University School of Medicine, and director of Quality Improvement for the Emory Hospital Medicine Unit.
Though we expect to continue working with sites enrolled in the mentoring program for many more months, the collaborative has been in place long enough that we can start evaluating outcomes and thinking about what we’ve learned.
In all, 35 hospitals so far have enrolled in the collaborative: three in the consultation program and 32 in the mentoring program. Because the participants enrolled in the mentoring program generally were starting from an earlier point in the QI process (i.e., thinking about starting a project vs. trying to improve an existing effort), we’ve focused our evaluation attention on them.
At the time of enrollment, 33% of these sites were thinking of starting a VTE-prevention project, 42% had an active QI project but had not yet implemented any interventions, and 25% had an active QI project and had implemented an intervention (i.e., a new order set or risk-assessment protocol).
We surveyed the 21 sites that have been involved in the mentoring program for at least six months, asking about the status of their VTE-prevention project and their experiences working with SHM mentors. So far, 15 have responded to the survey, and the results are quite interesting.
Since becoming involved with the collaborative, nearly every participant had made significant progress with their project:
- 94% had redesigned the processes for assessing VTE risk and bleeding risk and providing appropriate prophylaxis;
- 100% had selected a VTE risk assessment model, and 88% had developed prophylaxis recommendations for each level of risk;
- 100% had defined absolute and relative contraindications to pharmacologic prophylaxis and recommendations for what to do if they exist;
- 100% had developed order sets or protocols that encourage initial assessment of VTE risk and provision of appropriate prophylaxis; and
- 75% had developed order sets or protocols in use at their hospitals.
All seven sites that had a baseline figure that could be used for comparison reported their current rate of appropriate VTE prophylaxis is higher than it was before they became involved in the collaborative.
We asked participants to identify the topics with which they were helped by their mentors. The responses showed the breadth of issues that need attention to create a successful QI project. The topics covered and percentage of enrollees who sought help with them include:
- Defining the goals, aims and scope of your project, 93%;
- Redesigning your VTE prevention process, 87%;
- Developing risk assessment and prophylaxis recommendations, 87%;
- Developing order sets and protocols, 87%;
- Data collection and measurement, 87%;
- Piloting and revising risk assessment tools, order sets and protocols, 60%;
- Securing institutional support for your project, 47%;
- Assembling your project team, 47%;
- Mapping the original (pre-collaborative involvement) VTE prevention process at your site, 40%;
- Identifying and securing support from key stakeholders, 33%; and
- Developing educational/outreach strategies or materials, 27%.